Moderna Therapeutics
Biotech
Cambridge, Massachusetts

Overall Rank: 11
Category: Biotechnology
Category Rank: 6

Awards:

  • Top HealthTech Company of 2023

Profile

In 10 years since its inception, Moderna has transformed from a science research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for both clinical and commercial production at scale and at unprecedented speed. Moderna maintains alliances with a broad range of domestic and overseas government and commercial collaborators, which has allowed for the pursuit of both groundbreaking science and rapid scaling of manufacturing. Most recently, Moderna’s capabilities have come together to allow the authorized use of one of the earliest and most effective vaccines against the COVID-19 pandemic.


Moderna’s mRNA platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, and has allowed the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases and auto-immune diseases. Moderna has been named a top biopharmaceutical employer by Science for the past seven years.


Visit: www.modernatx.com


Become a Premium Subscriber

Please purchase a premium subscription to continue reading this report.

Subscribe Now

Key Products

mRNA DESIGN STUDIO™


Our mRNA DESIGN STUDIO enables rapid design of multiple mRNAs. As the DIGITAL BIOTECH COMPANY™, Moderna maximizes the utility of mRNA in our proprietary, web-based mRNA DESIGN STUDIO.


mRNA EARLY DEVELOPMENT ENGINE™ services combine internal and external capabilities for process development, toxicology studies, global regulatory interactions, and clinical study preparation and execution for our mRNA vaccines and therapeutics.


These services are designed to deliver many investigational mRNA vaccines and therapeutics to human proof of concept data.


Key Executives

Stéphane Bancel, Chief Executive Officer


Stéphane Bancel has served as Moderna’s Chief Executive Officer since October 2011 and as a member of Moderna’s board of directors since March 2011. Before joining the company, Mr. Bancel served for five years as Chief Executive Officer of the French diagnostics company bioMérieux SA. From July 2000 to March 2006, he served in various roles at Eli Lilly and Company, including as Managing Director, Belgium and as Executive Director, Global Manufacturing Strategy and Supply Chain. Prior to Lilly, Mr. Bancel served as Asia-Pacific Sales and Marketing Director for bioMérieux.


Mr. Bancel currently serves on the board of directors of Indigo. He is currently a Venture Partner at Flagship Pioneering. Mr. Bancel holds a Master of Engineering degree from École Centrale Paris (ECP), a Master of Science in chemical engineering from the University of Minnesota, and an M.B.A. from Harvard Business School.


Stephen Hoge, M.D., President


Stephen Hoge serves as the President of Moderna and the head of Research & Development for the company. Dr. Hoge has led Moderna’s science for nearly 10 years, including the creation of our platform and therapeutic areas. He currently leads all R&D, from basic science through clinical development and regulatory. Dr. Hoge joined Moderna in late 2012 from McKinsey & Company, where he was a partner in the healthcare practice. Prior to McKinsey, Dr. Hoge was a resident physician in New York City.


Juan Andres, President, Strategic Partnerships and Enterprise Expansion


As President, Strategic Partnerships and Enterprise Expansion, Mr. Andres is focused on building out Moderna’s organization to support the Company’s growing mRNA pipeline.

Mr. Andres joined Moderna in 2017 and most recently served as Chief Technical Operations and Quality Officer. Before joining Moderna, Mr. Andres was the Global Head of Technical Operations, Manufacturing and Supply Chain at Novartis for over 25,000 employees across all of its divisions. Prior to Novartis, Juan worked at Eli Lilly & Co. for 18 years in a variety of manufacturing, production and quality roles in the United States, Puerto Rico, UK and Spain.


Mr. Andres holds a Master degree in Pharmacy from Alcala de Henares University in Madrid and completed an advanced development program at the London Business School.


Paul Burton, M.D., Chief Medical Officer


As Chief Medical Officer, Paul Burton oversees medical affairs and safety.

Dr. Burton joined Moderna after spending sixteen years with Johnson & Johnson. Since March 2020, he served as Chief Global Medical Affairs Officer of Janssen Pharmaceuticals where he was responsible for Janssen’s worldwide medical affairs strategy and execution. Previously, he served as Janssen’s Vice President and Head, Cardiovascular and Metabolic Medical Affairs. Dr. Burton also led the Johnson & Johnson collaboration with APPLE for the digital HEARTLINE™ study, and previously led clinical operations for all therapeutic areas across the Americas. Dr. Burton has an M.D. from the University of London, is board certified in surgery and is a Member of the Royal College of Surgeons with specialist training in cardiothoracic surgery. He holds a Ph.D. in cardiovascular molecular and cellular biology from Imperial College in London and is a Fellow of the American College of Cardiology. He has published extensively in peer-reviewed journals.


Jerh Collins, Ph.D., Chief Technical Operations and Quality Officer


As Chief Technical Operations and Quality Officer, Dr. Collins is responsible for the technical development, quality, and supply of preclinical, clinical and commercial programs within Moderna’s portfolio. Dr. Collins joined Moderna from Novartis, where he held roles of increasing responsibility over the last nearly 30 years, focused on pharmaceutical production and manufacturing, including roles serving as Head of Global Chemical Operations and Anti-Infectives and as Head of Global Chemical Operations. Dr. Collins received his Bachelor of Science in Chemistry and his Ph.D. in Organic Chemistry from University College Cork, Ireland. He also conducted post-doctoral cancer research at Arizona State University.


Kate Cronin, Chief Brand Officer


As Chief Brand Officer, Kate Cronin is responsible for amplifying Moderna’s story and the promise of mRNA science for patients. Ms. Cronin joined Moderna from Ogilvy Health, part of WPP plc., where she served as Global CEO. In this role, she led the full spectrum of Ogilvy Health’s core capabilities including public relations and influence, brand strategy, advertising, medical education, market access, and patient and consumer engagement. Additionally, Ms. Cronin grew Ogilvy’s business in the health and wellness arena, encompassing a broad portfolio including pharmaceuticals, consumer health, insurance, hospitals, health technology and medical devices. Ms. Cronin led integrated campaigns involving social, digital, brand and public relations for Ogilvy’s largest, long-term health clients including BMS, Boehringer Ingelheim, Merck and Pfizer. Prior to her role as CEO, Ms. Cronin held numerous leadership roles within Ogilvy including Global Managing Director, Managing Director of Ogilvy Public Relations’ New York office, and most recently Co-President of Ogilvy Health in the United States. Before her 17-year tenure at Ogilvy, Ms. Cronin was a Partner at Porter Novelli. Before starting her career in communications, Ms. Cronin conducted research in the field of neurobiology at Cornell University Medical College. She co-authored several research articles focused on learning and memory and published in peer-reviewed publications. Ms. Cronin received a Bachelor of Arts in biology from Smith College.


Marcello Damiani, Chief Digital and Operational Excellence Officer


As Chief Digital and Operational Excellence Officer, Marcello Damiani brings a wealth of experience from both Tech companies and Life Science companies and a true passion for making Digital a reality. He has 20 years experience working in the IT field, with the last 10 years being spent in leadership roles for multinational companies in Europe and in the U.S.

Prior to joining Moderna, Mr. Damiani was instrumental in conceiving and building creative IT solutions to help solve business challenges, first at Motorola and then at bioMérieux. His expertise is in visioning, strategizing and implementing innovative programs to update and streamline the digital landscapes. He is known for his ability to transform a company’s Information flow, and ultimately improving the product and the company’s processes through digitization. Mr. Damiani possesses a Master of Science degree in Information Systems Architecture from the University of Toulouse in France, and an international Executive MBA through TRIUM, an alliance of three of the world’s top universities: the London School of Economics, New York University’s Stern Business School, and the HEC School of Management in Paris.


Tracey Franklin, Chief Human Resources Officer


As Chief Human Resources Officer, Tracey Franklin leads Moderna’s talent and organizational strategy. Ms. Franklin joined Moderna following 15 years at Merck & Co., Inc. where she most recently led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer and served on Merck’s HR Leadership Team. In this role, Ms. Franklin was responsible for leading the vision, development and execution of the company’s Talent and Workforce Strategy with a focus on evolving the organizational culture and talent for the future. Ms. Franklin’s previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. She was based in Switzerland, the U.K. and the U.S. Ms. Franklin holds a bachelor’s in communication arts and sciences from Pennsylvania State University and a Master in industrial and organizational psychology from Fairleigh Dickinson University.


Arpa Garay, Chief Commercial Officer


As Chief Commercial Officer, Arpa Garay leads Moderna’s global commercial organization.


Ms. Garay joined Moderna from Merck & Co., Inc. (MRK) where she most recently served as Chief Marketing Officer for Merck’s Human Health business; she reported to Merck’s Chief Executive Officer and was a member of Merck’s Executive Committee. In this role, she was responsible for long-term portfolio strategy and global marketing for Merck’s in-line and pipeline human health medicines and vaccines, including global market access and pricing strategy, data and analytics, digital marketing, and commercial business development.  During Ms. Garay’s 16-year tenure at Merck, she gained broad international enterprise with increasing responsibility across oncology, vaccines, specialty, and chronic care. Prior to her role as Chief Marketing Officer, Ms. Garay served as President of Global Oncology and Digital at MSD. Additionally, she was responsible for data & analytics, digital marketing, and precision medicine worldwide. She also served as President of Global Pharmaceuticals, Analytics, and Digital Marketing; SVP & Head of U.S. Vaccines; and General Manager of Merck & Co. in Norway. Ms. Garay has lived in five countries including Hong Kong, India, Norway, Singapore, and the U.S.  Ms. Garay received her Bachelor of Science in economics from the Massachusetts Institute of Technology, where she focused on medicine, public health and public policy.


Jamey Mock, Chief Financial Officer


As Chief Financial Officer, Jamey Mock oversees financial, business development and business services functions at Moderna. Mr. Mock previously served as Senior Vice President and CFO of PerkinElmer, Inc., a life sciences, diagnostics and analytical solutions company, since May 2018. In his role at PerkinElmer, he had overall leadership responsibility for the strategy and operations of all Company finance functions. During that time, he was instrumental in transforming PerkinElmer into an organization with a strengthened financial profile for growth and profitability. Before that, Mr. Mock served for nearly 20 years in a wide range of financial oversight capacities within General Electric Company, both in the United States and overseas. Mr. Mock holds a Bachelor of Arts in economics from St. Lawrence University.


Company Responsibility

Environment


Moderna has pledged to achieve net-zero carbon emissions by 2030. Their other initiatives include fully subsidized green transportation across our campuses and manufacturing that uses 50% less water. They are passionate about being an active contributor to the communities where they live and work, as well as to global communities through their charity and learning initiatives.They are dedicated to upholding the highest ethical standards in their clinical trials, manufacturing process and conduct in our internal and external relationships.


Employees


Moderna employees drive their achievements in bringing innovative medicines to patients. Their commitment to them is rooted in an inclusive environment that fosters well-being. They believe that we will only succeed in their goals if they are able to attract and retain individuals of diverse backgrounds and of all ages, genders, ethnicities, religions, home countries and sexual orientations. Benefits like professional development programs, 401(k) matching, stock options and generous paid leave mean their team is empowered to achieve great things.


The company launched the Moderna Charitable Foundation in 2022 to support organizations and causes that promote public health and access to quality healthcare, advancing scientific education and innovation, and advocating for diversity and inclusion, particularly in underserved populations.


The Moderna Foundation is an extension of the societal impact they have made with their COVID-19 vaccine. They are passionate about addressing the ongoing needs in communities impacted by COVID-19, including the societal conditions exacerbated by the pandemic along with the inequalities this challenging period has revealed.


Company insights

“We as a company care deeply—about our patients, our employees, the environment and our communities. We recognize that we have an opportunity to change medicine for all, and we will continue to make corporate responsibility a critical part of who we are and what we do.” – Stéphane Bancel


 


“We believe our mRNA platform can solve the world’s greatest health challenges, from diseases impacting millions, to ultra-rare diseases impacting dozens, to medicines personalized down to the individual level.” – Stéphane Bancel, Chief Executive Officer


 


“Collaboration at Moderna is like an orchestra. Each area plays a different role, but it’s all of the same tune.” – Lilly Medeiros, Engineer in Early Development Operations


 


“You never see someone struggling by themselves. Everyone’s super helpful and ready to jump in. Many hands really do make light work!” – Eamon Donovan, Manufacturing Associate


 


“Seeing the impact of mRNA technology in the world today, it gave me a flashback of why I joined this company. That’s something I’m going to be proud of for the rest of my life.” – Chisom Udengwu, Senior Research Associate